Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study concluded that administering dutasteride for more than 8 weeks in rats could lead to irreversible erectile dysfunction, even after stopping the medication.

In this study, men using Propecia for alopecia showed normal erectile hemodynamics despite erectile dysfunction after stopping 5-alpha reductase inhibitors, while some BPH patients exhibited abnormal results potentially linked to vascular risk factors.

This review discusses persistent adverse effects of 5α‐reductase inhibitors, like diminished libido and erectile dysfunction, in some patients and highlights the need for patient discussions before therapy, especially for androgenetic alopecia.

This study used high-resolution ultrasound to investigate the pathophysiology of persistent erectile dysfunction in young men who used the drug finasteride, observing differences in erectile tissue homogeneity compared to control subjects without finasteride exposure.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Long use of finasteride and dutasteride can cause long-term erection problems.

In this study, men with persistent sexual dysfunction after stopping finasteride showed significant vascular, neurologic, and hormonal abnormalities, with severe erectile dysfunction being common.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

Finasteride use may cause sexual dysfunction; more research needed.

Finasteride, a hair loss drug, can cause long-lasting sexual side effects like low libido and erectile dysfunction.

This paper reports on the controversy surrounding post-finasteride syndrome and questions Merck and the FDA's handling of associated sexual side effects. Despite significant adverse event reports, both entities failed to conduct further studies or enhance patient safety warnings about finasteride's long-term effects.

In this study, mild improvements in erectile function, penile sensitivity, and nocturnal erections were observed in male patients with post-drug syndrome following a 16-week treatment targeting the peripheral nerves of the genitalia, but significant symptoms persisted, indicating further research is essential.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This study found that young men with post-finasteride syndrome may experience erectile dysfunction due to potential histologic changes in penile tissue, despite having normal penile Doppler hemodynamics.

This review discusses concerns about persistent side effects of finasteride, such as sexual dysfunction and suicidal ideation, urging the medical community to recognize and address these issues.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

The authors concluded that finasteride and dutasteride might have serious side effects, including persistent sexual dysfunction for some, necessitating further research and vigilant risk-benefit analysis.

In this study, men with previous finasteride use reported more severe sexual and psychological symptoms with greater cumulative exposure and older age, highlighting a need for further research on risk factors and long-term impacts.

This review discusses the adverse effects of finasteride for male androgenic alopecia, highlighting depressive symptoms and persistent sexual dysfunction, and reports no new clinical findings.

This review discusses the efficacy and safety of oral finasteride for treating male pattern baldness and the potential persistent side effects, but no new results are reported.

This study examined lawsuits in Canada involving 5α-reductase inhibitors, revealing that all cases related to persistent erectile dysfunction as a side effect in men treated for hair loss, but no judgments have been made yet against physicians or pharmaceutical companies.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review identifies evidence of sexual adverse effects, particularly linked to finasteride, in men using systemic dermatologic medications but reports no new clinical findings.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.